Logo image of AVDL

AVADEL PHARMACEUTICALS (AVDL) Stock Overview

NASDAQ:AVDL - IE00BDGMC594 - Common Stock

14.81 USD
-0.43 (-2.82%)
Last: 8/25/2025, 5:25:23 PM
14.88 USD
+0.07 (+0.47%)
After Hours: 8/25/2025, 5:25:23 PM

AVDL Key Statistics, Chart & Performance

Key Statistics
52 Week High16.66
52 Week Low6.38
Market Cap1.34B
Shares90.58M
Float86.15M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.03
PEN/A
Fwd PE18.31
Earnings (Next)11-10 2025-11-10/bmo
IPO01-16 1952-01-16
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


AVDL short term performance overview.The bars show the price performance of AVDL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80

AVDL long term performance overview.The bars show the price performance of AVDL in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40 60 80 100

The current stock price of AVDL is 14.81 USD. In the past month the price increased by 36.75%. In the past year, price decreased by -2.37%.

AVADEL PHARMACEUTICALS / AVDL Daily stock chart

AVDL Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 43.05 658.10B
JNJ JOHNSON & JOHNSON 17.84 429.67B
NVO NOVO-NORDISK A/S-SPONS ADR 14.52 250.34B
AZN ASTRAZENECA PLC-SPONS ADR 17.94 246.98B
NVS NOVARTIS AG-SPONSORED ADR 14.13 242.06B
MRK MERCK & CO. INC. 11.08 213.09B
PFE PFIZER INC 7.42 142.93B
SNY SANOFI-ADR 11.37 122.26B
BMY BRISTOL-MYERS SQUIBB CO 7 95.95B
GSK GSK PLC-SPON ADR 8.83 79.91B
ZTS ZOETIS INC 24.95 68.78B
TAK TAKEDA PHARMACEUTIC-SP ADR 51.97 47.59B

About AVDL

Company Profile

AVDL logo image Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 188 full-time employees. The firm's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Company Info

AVADEL PHARMACEUTICALS

Block 10-1 Blanchardstown Corporate Park, Ballycoolin

DUBLIN DUBLIN D02 IE

CEO: Gregory J. Divis

Employees: 188

AVDL Company Website

AVDL Investor Relations

Phone: 35319015201

AVADEL PHARMACEUTICALS / AVDL FAQ

What is the stock price of AVADEL PHARMACEUTICALS today?

The current stock price of AVDL is 14.81 USD. The price decreased by -2.82% in the last trading session.


What is the ticker symbol for AVADEL PHARMACEUTICALS stock?

The exchange symbol of AVADEL PHARMACEUTICALS is AVDL and it is listed on the Nasdaq exchange.


On which exchange is AVDL stock listed?

AVDL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AVADEL PHARMACEUTICALS stock?

14 analysts have analysed AVDL and the average price target is 19.51 USD. This implies a price increase of 31.72% is expected in the next year compared to the current price of 14.81. Check the AVADEL PHARMACEUTICALS stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AVADEL PHARMACEUTICALS worth?

AVADEL PHARMACEUTICALS (AVDL) has a market capitalization of 1.34B USD. This makes AVDL a Small Cap stock.


How many employees does AVADEL PHARMACEUTICALS have?

AVADEL PHARMACEUTICALS (AVDL) currently has 188 employees.


What are the support and resistance levels for AVADEL PHARMACEUTICALS (AVDL) stock?

AVADEL PHARMACEUTICALS (AVDL) has a support level at 13.47 and a resistance level at 15.25. Check the full technical report for a detailed analysis of AVDL support and resistance levels.


Is AVADEL PHARMACEUTICALS (AVDL) expected to grow?

The Revenue of AVADEL PHARMACEUTICALS (AVDL) is expected to grow by 60.93% in the next year. Check the estimates tab for more information on the AVDL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy AVADEL PHARMACEUTICALS (AVDL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AVADEL PHARMACEUTICALS (AVDL) stock pay dividends?

AVDL does not pay a dividend.


When does AVADEL PHARMACEUTICALS (AVDL) report earnings?

AVADEL PHARMACEUTICALS (AVDL) will report earnings on 2025-11-10, before the market open.


What is the Price/Earnings (PE) ratio of AVADEL PHARMACEUTICALS (AVDL)?

AVADEL PHARMACEUTICALS (AVDL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.03).


What is the Short Interest ratio of AVADEL PHARMACEUTICALS (AVDL) stock?

The outstanding short interest for AVADEL PHARMACEUTICALS (AVDL) is 12.59% of its float. Check the ownership tab for more information on the AVDL short interest.


AVDL Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to AVDL. When comparing the yearly performance of all stocks, AVDL is one of the better performing stocks in the market, outperforming 86.68% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

AVDL Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to AVDL. AVDL is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AVDL Financial Highlights

Over the last trailing twelve months AVDL reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 97.37% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -1.56%
ROE -3.22%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%171.43%
Sales Q2Q%64.15%
EPS 1Y (TTM)97.37%
Revenue 1Y (TTM)132.35%

AVDL Forecast & Estimates

14 analysts have analysed AVDL and the average price target is 19.51 USD. This implies a price increase of 31.72% is expected in the next year compared to the current price of 14.81.

For the next year, analysts expect an EPS growth of 146.52% and a revenue growth 60.93% for AVDL


Analysts
Analysts84.29
Price Target19.51 (31.74%)
EPS Next Y146.52%
Revenue Next Year60.93%

AVDL Ownership

Ownership
Inst Owners83.09%
Ins Owners4.83%
Short Float %12.59%
Short Ratio7.69